Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 12 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/4/2005 First Published: 8/1/1998


1.		Phase III Randomized Study of Prednisone Alone or in Combination with BMS-182751 in Patients with Advanced Hormone Refractory Adenocarcinoma of the Prostate (Summary Last Modified 09/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Over 18								EORTC-30972 BMS-CA142-025

Last Modified: 8/1/1999 First Published: 4/1/1999


2.		Phase III Randomized Study of BMS-182751 Plus Prednisone versus Prednisone Alone in Patients with Symptomatic Hormone-Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				Over 18				Pharmaceutical / Industry				BMS-CA142-029


3.		Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				GPC SAT3-03-01 NCT00069745


4.		Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				SAT3-06-04 NCT00450970


5.		Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				SAT1-04-02 NCT00093132

Last Modified: 7/1/1995


6.		Phase II Study of Oral BMS-182751 (a Platinum Compound) for Nonsmall Cell Lung Cancer (Summary Last Modified 07/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over								EORTC-16942N

Last Modified: 7/1/1999


7.		Phase II Study of BMS-182751 for Advanced or Recurrent Squamous Cell Carcinoma of the Cervix (Summary Last Modified 07/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				16 and over				Pharmaceutical / Industry				CAN-NCIC-IND102 BMS-182751, IND102


8.		Satraplatin for Patients With Metastatic Breast Cancer (MBC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				Protocol 05-021 NCT00265655


9.		Satraplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				SAT2-05-05 NCT00268970


10.		A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-Small-Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				70 and over				Pharmaceutical / Industry				SAT2-05-07 NCT00370383

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute